{"id":"anti-ige-therapy-xolair","safety":{"commonSideEffects":[{"rate":"45","effect":"Injection site reaction"},{"rate":"12","effect":"Headache"},{"rate":"11","effect":"Upper respiratory tract infection"},{"rate":"8","effect":"Arthralgia"},{"rate":"6","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108941","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By sequestering free IgE in the bloodstream, omalizumab reduces the amount of IgE available to cross-link receptors on mast cells and basophils, thereby suppressing the release of inflammatory mediators (histamine, tryptase, leukotrienes) that drive allergic and asthmatic responses. This mechanism reduces both the immediate hypersensitivity reaction and downstream allergic inflammation.","oneSentence":"Xolair (omalizumab) is a monoclonal antibody that binds to circulating IgE, preventing it from interacting with high-affinity IgE receptors on mast cells and basophils.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:25.447Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe allergic asthma"},{"name":"Chronic idiopathic urticaria"},{"name":"Severe allergic reactions to specific allergens"}]},"trialDetails":[{"nctId":"NCT07059091","phase":"PHASE2","title":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Allergies","enrollment":334},{"nctId":"NCT07342803","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients","status":"RECRUITING","sponsor":"Longbio Pharma","startDate":"2025-01-25","conditions":"Allergic Asthma","enrollment":200},{"nctId":"NCT03369704","phase":"PHASE3","title":"Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-15","conditions":"Seasonal Allergic Rhinitis","enrollment":337},{"nctId":"NCT04998604","phase":"PHASE4","title":"EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-09-27","conditions":"Chronic Rhinosinusitis With Nasal Polyps, Asthma","enrollment":360},{"nctId":"NCT03881696","phase":"PHASE3","title":"Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-22","conditions":"Peanut Allergy, Multi-food Allergy","enrollment":471},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06437171","phase":"PHASE4","title":"FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA","status":"ACTIVE_NOT_RECRUITING","sponsor":"AAADRS Clinical Research Center","startDate":"2024-06-03","conditions":"Food Allergy","enrollment":20},{"nctId":"NCT06934200","phase":"PHASE2","title":"Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-05-19","conditions":"Food Hypersensitivity","enrollment":32},{"nctId":"NCT04833855","phase":"PHASE2","title":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-04-15","conditions":"Chronic Spontaneous Urticaria","enrollment":183},{"nctId":"NCT03727971","phase":"PHASE2","title":"Treatment With the Anti-IgE Monoclonal Antibody Omalizumab in Women With Asthma Undergoing Fertility Treatment. - A Proof of Concept Study.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2019-01-01","conditions":"Asthma, Infertility, Female","enrollment":66},{"nctId":"NCT06771934","phase":"","title":"Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qianfoshan Hospital","startDate":"2024-06-01","conditions":"Allergic Asthma","enrollment":60},{"nctId":"NCT03580356","phase":"PHASE3","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-20","conditions":"Chronic Spontaneous Urticaria","enrollment":1078},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":"Pediatric Asthma, Rhinitis, Allergic, Quality of Life","enrollment":600},{"nctId":"NCT05270278","phase":"","title":"Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy","status":"COMPLETED","sponsor":"Value Outcomes Ltd.","startDate":"2022-08-16","conditions":"Asthma; Eosinophilic, Asthma Chronic, Bronchial Asthma","enrollment":89},{"nctId":"NCT04037176","phase":"PHASE4","title":"Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)","status":"COMPLETED","sponsor":"Carsten Bindslev-Jensen","startDate":"2019-11-01","conditions":"Food Allergy","enrollment":20},{"nctId":"NCT04158050","phase":"","title":"Comparison of Biologicals in Treatment of Severe Asthma","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2018-01-01","conditions":"Asthma","enrollment":64},{"nctId":"NCT06027073","phase":"PHASE4","title":"Biologics and Sublingual Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Silesia","startDate":"2024-05-01","conditions":"Asthma, Allergic","enrollment":150},{"nctId":"NCT03580369","phase":"PHASE3","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-17","conditions":"Chronic Spontaneous Urticaria","enrollment":1072},{"nctId":"NCT05129033","phase":"NA","title":"A Prospective Study on Optimizing Treatment for ABPA","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-11-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":100},{"nctId":"NCT04535817","phase":"PHASE1","title":"Xolair Interventional Study in ASD Patients With Comorbid Atopy","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-01-01","conditions":"Autism Spectrum Disorder, Atopy","enrollment":""},{"nctId":"NCT00367016","phase":"PHASE4","title":"Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2004-02","conditions":"Asthma, Allergic Rhinitis, Atopic Dermatitis","enrollment":6},{"nctId":"NCT04489121","phase":"NA","title":"The Efficacy of Preseasonal Omalizumab Treatment","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2020-07-28","conditions":"Seasonal Allergic Rhinitis","enrollment":31},{"nctId":"NCT04607629","phase":"PHASE3","title":"An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-06-20","conditions":"Bronchial Asthma","enrollment":192},{"nctId":"NCT01723072","phase":"PHASE3","title":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-01-23","conditions":"Chronic Spontaneous Urticaria, Angioedema","enrollment":91},{"nctId":"NCT01157117","phase":"PHASE2","title":"OIT and Xolair® (Omalizumab) in Cow's Milk Allergy","status":"COMPLETED","sponsor":"Hugh A Sampson, MD","startDate":"2010-08","conditions":"Milk Allergy","enrollment":77},{"nctId":"NCT03280550","phase":"PHASE3","title":"A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-11-15","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":138},{"nctId":"NCT03280537","phase":"PHASE3","title":"A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-11-21","conditions":"Nasal Polyps, Chronic Rhinosinusitis","enrollment":127},{"nctId":"NCT00603785","phase":"PHASE4","title":"Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2008-01","conditions":"Chronic Sinusitis","enrollment":""},{"nctId":"NCT03361111","phase":"","title":"BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2013-04-04","conditions":"Severe Asthma","enrollment":16},{"nctId":"NCT02658877","phase":"PHASE4","title":"Sputum-derived Cellular Targets After Xolair (Omalizumab)","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2016-01","conditions":"Asthma","enrollment":3},{"nctId":"NCT00189228","phase":"NA","title":"Immune Dysfunction in Allergic Asthma","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2005-09","conditions":"Asthma","enrollment":18},{"nctId":"NCT01912872","phase":"PHASE4","title":"Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-11","conditions":"Severe IgE-mediated Asthma","enrollment":112},{"nctId":"NCT02012387","phase":"PHASE2","title":"Efficacy Study of Omalizumab in Cholinergic Urticaria","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2014-01","conditions":"Cholinergic Urticaria","enrollment":24},{"nctId":"NCT02402231","phase":"PHASE2","title":"Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy","status":"UNKNOWN","sponsor":"Caroline Nilsson","startDate":"2013-10","conditions":"Peanut Allergy","enrollment":23},{"nctId":"NCT00264849","phase":"PHASE4","title":"Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Asthma","enrollment":406},{"nctId":"NCT00932282","phase":"PHASE1, PHASE2","title":"Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-07","conditions":"Peanut Hypersensitivity","enrollment":13},{"nctId":"NCT00283504","phase":"PHASE4","title":"A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy","status":"COMPLETED","sponsor":"Children's Hospital of The King's Daughters","startDate":"2006-01","conditions":"ALLERGIC ASTHMA","enrollment":13},{"nctId":"NCT01713725","phase":"PHASE2","title":"Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2012-03","conditions":"Chronic Urticaria","enrollment":20},{"nctId":"NCT01716754","phase":"PHASE2","title":"Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Asthma","enrollment":471},{"nctId":"NCT00949078","phase":"PHASE2","title":"Omalizumab in the Treatment of Peanut Allergy","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-07","conditions":"Food Allergy, Peanut Allergy","enrollment":51},{"nctId":"NCT01066104","phase":"PHASE2","title":"Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-12","conditions":"Chronic Rhinosinusitis, Nasal Polyps","enrollment":27},{"nctId":"NCT00096954","phase":"PHASE4","title":"A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-02","conditions":"Asthma","enrollment":333},{"nctId":"NCT00495612","phase":"PHASE4","title":"A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-09","conditions":"Asthma","enrollment":69},{"nctId":"NCT01430403","phase":"PHASE4","title":"Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Asthma","enrollment":478},{"nctId":"NCT00604786","phase":"NA","title":"The Effect of Omalizumab on Responses to Cat Allergen Challenge","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2007-07","conditions":"Allergic Rhinitis","enrollment":18},{"nctId":"NCT00377572","phase":"PHASE4","title":"Inner-City Anti-IgE Therapy for Asthma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Asthma","enrollment":419},{"nctId":"NCT00078195","phase":"PHASE2","title":"Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-04","conditions":"Hay Fever, Hypersensitivity, Allergy","enrollment":168},{"nctId":"NCT00267202","phase":"PHASE4","title":"Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Allergic Asthma","enrollment":275},{"nctId":"NCT00123630","phase":"PHASE2","title":"A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-11","conditions":"Esophagitis","enrollment":30},{"nctId":"NCT01703312","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Allergic Asthma","enrollment":37},{"nctId":"NCT01976208","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma","status":"COMPLETED","sponsor":"Shanghai Zhangjiang Biotechnology Limited Company","startDate":"2010-12","conditions":"Allergic Asthma","enrollment":630},{"nctId":"NCT01599637","phase":"PHASE2","title":"Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-04","conditions":"Chronic Idiopathic Urticaria","enrollment":40},{"nctId":"NCT01202903","phase":"PHASE3","title":"Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Persistent Allergic Asthma","enrollment":616},{"nctId":"NCT01544348","phase":"PHASE1","title":"A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-01","conditions":"Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis","enrollment":295},{"nctId":"NCT01125748","phase":"PHASE4","title":"A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-05","conditions":"Allergic Asthma","enrollment":176},{"nctId":"NCT01003301","phase":"PHASE2","title":"The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-10","conditions":"Cat Allergy","enrollment":19},{"nctId":"NCT00139152","phase":"PHASE4","title":"Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-09","conditions":"Lung Disease","enrollment":65},{"nctId":"NCT00377390","phase":"","title":"ICATA Asthma Mechanistic Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Asthma","enrollment":224},{"nctId":"NCT00670930","phase":"PHASE4","title":"Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT00472030","phase":"PHASE4","title":"Efficacy and Safety of Omalizumab in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2007-08","conditions":"Bullous Pemphigoid","enrollment":2},{"nctId":"NCT01007149","phase":"PHASE3","title":"Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Asthma","enrollment":79},{"nctId":"NCT00673218","phase":"PHASE4","title":"The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils","status":"UNKNOWN","sponsor":"Creighton University","startDate":"2007-06","conditions":"Allergy","enrollment":25},{"nctId":"NCT00079937","phase":"PHASE3","title":"Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"Asthma","enrollment":628},{"nctId":"NCT00870584","phase":"PHASE4","title":"Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-03","conditions":"Persistent Allergic Asthma","enrollment":271},{"nctId":"NCT00481676","phase":"PHASE2","title":"Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-05","conditions":"Chronic Urticaria","enrollment":49},{"nctId":"NCT00454051","phase":"PHASE4","title":"Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Asthma","enrollment":31},{"nctId":"NCT01393340","phase":"PHASE2","title":"Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2006-12","conditions":"Nasal Polyposis, Asthma","enrollment":23},{"nctId":"NCT00567476","phase":"PHASE4","title":"Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Asthma","enrollment":116},{"nctId":"NCT01294878","phase":"PHASE3","title":"Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2009-03","conditions":"Interstitial Cystitis, Painful Bladder Syndrome","enrollment":3},{"nctId":"NCT00691873","phase":"PHASE4","title":"Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids","status":"COMPLETED","sponsor":"University of Mississippi Medical Center","startDate":"2006-05","conditions":"Asthma","enrollment":14},{"nctId":"NCT00329381","phase":"PHASE4","title":"Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy","status":"COMPLETED","sponsor":"University of Mississippi Medical Center","startDate":"2006-05","conditions":"Asthma","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ANTI-IGE THERAPY (XOLAIR)","genericName":"ANTI-IGE THERAPY (XOLAIR)","companyName":"Children's Hospital of The King's Daughters","companyId":"children-s-hospital-of-the-king-s-daughters","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xolair (omalizumab) is a monoclonal antibody that binds to circulating IgE, preventing it from interacting with high-affinity IgE receptors on mast cells and basophils. Used for Moderate to severe allergic asthma, Chronic idiopathic urticaria, Allergic rhinitis (off-label use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}